Mesoblast (NASDAQ:MESO) Stock Price Passes Below 50-Day Moving Average – Time to Sell?

Mesoblast Limited (NASDAQ:MESO) shares passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $18.19 and traded as low as $16.50. Mesoblast shares last traded at $16.67, with a volume of 144,397 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Mesoblast in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.

Mesoblast Stock Down 1.3%

The company has a quick ratio of 1.77, a current ratio of 1.99 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $2.15 billion, a P/E ratio of -18.94 and a beta of 2.15. The company has a fifty day moving average price of $18.19 and a 200-day moving average price of $16.81.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of MESO. Tobias Financial Advisors Inc. increased its position in Mesoblast by 38.3% in the fourth quarter. Tobias Financial Advisors Inc. now owns 13,828 shares of the company’s stock worth $249,000 after purchasing an additional 3,828 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Mesoblast in the 4th quarter worth $286,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Mesoblast in the 4th quarter worth about $34,000. Polen Capital Management LLC purchased a new stake in shares of Mesoblast during the 4th quarter valued at about $415,000. Finally, Legal & General Group Plc raised its position in shares of Mesoblast by 4.2% during the 4th quarter. Legal & General Group Plc now owns 679,023 shares of the company’s stock valued at $12,237,000 after buying an additional 27,607 shares in the last quarter. 1.43% of the stock is owned by hedge funds and other institutional investors.

About Mesoblast

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.